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Multidrug-Resistant MCF-7
Cells: An Identity Crisis?
Two recent correspondences pub-
lished in the Journal (1,2) labeled the
MCF-7/ADR cell line—a multidrug-
resistant (MDR) human breast cancer
MCF-7 subline—as having a non-
MCF-7 origin, which led to a change in
the nomenclature of this cell line to NCI/
ADR. We believe the original nomen-
clature of MCF-7/ADR should be re-
tained.
Although the two MDR MCF-7 sub-
lines (MCF-7/ADR and MCF-7 TH)
used by the investigators whose work
prompted the nomenclature change were
independently established, they showed
several genotypic and phenotypic simi-
larities. Both contained a full-length
functional caspase-3 protein (2), despite
complete loss of this protein in the pa-
rental MCF-7 cells because of a 47-
base-pair deletion in exon 3 of the
CASP-3 gene (3). Interestingly, several
features of the MCF-7/DOX subline es-
tablished in our laboratory several years
ago (4) were identical to those of the
MCF-7/ADR and MCF-7 TH cells but
different from those of the parental
MCF-7 cells (5). For example, similar to
MCF-7/ADR and MCF-7 TH cells, the
MCF-7/DOX cells showed high expres-
sion levels of P-glycoprotein (P-gp) and
of a protein cross-linking enzyme, tissue
transglutaminase; they also contained
the full-length caspase-3 protein (6). We
thus sought to determine whether the de-
velopment of drug resistance in MCF-7
cells represents selective selection and
expansion of an inherently resistant
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clone in the parental MCF-7 cell popu-
lation. We purchased MCF-7 cells from
the American Type Culture Collection
(lot 2015862; Manassas, VA) and
treated them with doxorubicin at 1 g/
mL. More than 99% of the MCF-7 cells
died within 1 week, but a few colonies
(an average of two colonies per T-75
flask were observed to grow in the pres-
ence of doxorubicin) of cells survived
about 3 weeks of continuous culture in
the presence of the drug. We expanded
these colonies and, to our surprise, the
newly established MCF-7 cell subline
(MCF-7/WT/DOX) exhibited several
biochemical features similar to those of
the MCF-7/DOX and MCF-7/ADR cells
but different from those of the parental
MCF-7 cells. The MCF-7/WT/DOX
cells showed high expression levels of
both P-gp and tissue transglutaminase
and contained full-length functional
caspase-3 protein (Fig. 1, A). Karyo-
typic analysis of the MCF-7, MCF-7/
DOX, and MCF-7/WT/DOX cell lines
revealed unique features that were
highly conserved in the drug-resistant
sublines but were quite distinct in the
parental MCF-7 cells (5).
MCF-7 cells express a truncated iso-
form of caspase-3 transcript, whereas
drug-resistant sublines express full-
length caspase-3 transcript. Thus, we
amplified the complementary DNA
(cDNA) from MCF-7 and MCF-7/WT/
DOX cells by polymerase chain reaction
(PCR) using primers specific for full-
length caspase-3 cDNA to further vali-
date the presence of a drug-resistant
clone in the parental MCF-7 cells. The
resulting PCR products were analyzed
for the presence of caspase-3 transcripts
by agarose gel electrophoresis and
ethidium bromide staining. The PCR
products of the MCF-7 cells contained a
predominant band corresponding to
truncated caspase-3 transcript (Fig. 1,
B); a minor band corresponding to full-
length caspase-3 transcript became evi-
dent after many PCR cycles on the am-
plified cDNA (Fig. 1, B, arrow). The
PCR-amplified products from the MCF-
7/DOX cells showed only a single band,
corresponding to the full-length cas-
pase-3 transcript. These results con-
firmed the presence of one or more
inherently resistant subclones in the pa-
rental MCF-7 cells that harbor the full-
length CASP-3 gene and are likely to
propagate into drug-resistant cell lines
in the presence of MDR-related drugs.
This possibility was further supported
by our inability to establish any doxoru-
bicin-resistant cell lines from two
MCF-7 single-cell clones. These results
appeared to be consistent with the find-
ings that caspase-3-deficient MCF-7
cells, when reconstituted with caspase-3
cDNA, become more susceptible to che-
motherapy-induced apoptosis (6). It is
likely that caspase-3-adequate MCF-7
subclones that propagate into drug-
resistant sublines have additional path-
ways that confer selective resistance of
these cells to chemotherapeutic agents.
Despite their high resistance to doxoru-
bicin, these cells are exquisitely sensi-
tive to certain apoptosis-inducing
agents. For example, Leoni et al. (7) ob-
served that MCF-7/ADR cells were
more sensitive to indanone-induced ap-
optosis than were the drug-sensitive
MCF-7 cells. In our experience, the
MCF-7/DOX cells were much more
sensitive to a staurosporine-induced ap-
optosis than were the parental MCF-7
cells (5).
Our research has demonstrated that
drug-resistant MCF-7 cell lines result
from parental MCF-7 cells that harbor
the full-length CASP-3 gene. In view of
these results, we suggest that the origi-
nal nomenclature of MCF-7/ADR for
MCF-7-derived drug-resistant sublines
be retained to reveal the fact that various
clones in a given tumor population can
be extremely diverse in terms of their
genotype and phenotypic characteristics.
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Fig. 1. Tissue transglutaminase (tTGase) and caspase-3 expression in MCF-7, MCF-7/WT/DOX, and
MCF-7/DOX cell lines. A) tTGase and caspase-3 protein expression levels were examined by western blot
analysis in the parental MCF-7 cells (purchased from American Type Culture Collection; lane 1), in
drug-resistant MCF-7/WT/DOX cells (obtained by continuous culture of the parental MCF-7 cells in
doxorubicin at 1 g/mL; lane 2), and in MCF-7/DOX cells (obtained from Dr. Ken Cowan, National
Cancer Institute; lane 3). B) Caspase-3 transcripts in MCF-7 cells (lane 1) and MCF-7/WT/DOX cells
(lane 2), as determined after many polymerase chain reaction cycles of the complementary DNA from the
respective cell lines. Arrow indicates the presence of full-length caspase-3 transcript in MCF-7 cells.
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RESPONSE
We read with great interest the cor-
respondence by Mehta et al. These au-
thors propose the hypothesis that the
various doxorubicin (ADR)-selected
MCF-7 sublines may result from the se-
lective expansion of inherently resistant
subclones that contaminate the parental
MCF-7 cell line and that harbor the full-
length CASP-3 gene. Although this
theory is quite interesting, we have some
caveats (1). Because the CASP-3 gene is
deleted in parental MCF-7 (1), it is
difficult to understand how this geno-
type could have been reverted in the
hypothetically inherently resistant sub-
clones (2). In our original descrip-
tion, we assessed the nonidentity of
MCF-7 and MCF-7 TH by DNA finger-
printing (2). This method is more reli-
able than phenotypic karyotyping (3).
When they claim that an inherently re-
sistant subclone contains functional
caspase-3, Mehta et al. somehow con-
tradict the finding that caspase-3 re-
stores chemotherapy sensitivity in
MCF-7 cells (3).
Most importantly, Mehta et al. ex-
plain their hypothesis with a contamina-
tion of the parental MCF-7 cell line.
Thus, we strongly caution against retain-
ing the original nomenclature—MCF-7/
ADR or MCF-7 TH—for these sublines
of unknown origin. Good research can-
not be performed with tools of uncertain
identity.
FARZANEH PIRNIA
MARKUS M. BORNER
REFERENCES
(1) Janicke RU, Sprengart ML, Wati MR, Porter
AG. Caspase-3 is required for DNA fragmen-
tation and morphological changes associated
with apoptosis. J Biol Chem 1998;273:
9357–60.
(2) Pirnia F, Breuleux M, Schneider E, Hochmeis-
ter M, Bates SE, Marti A, et al. Uncertain
identity of doxorubicin-resistant MCF-7 cell
lines expressing mutated p53. J Natl Cancer
Inst 2000;92:1535–6.
(3) Yang XH, Sladek TL, Liu X, Butler BR,
Froelich CJ, Thor AD. Reconstitution
of caspase-3 sensitizes MCF-7 breast
cancer cells to doxorubicin- and etoposide-
induced apoptosis. Cancer Res 2001;61:
348–54.
NOTES
Affiliation of authors: F. Pirnia, M. M. Borner,
Institute of Medical Oncology, Inselspital, Bern,
Switzerland.
Correspondence to: Markus M. Borner, M.D.,
University of Bern, Institute of Medical Oncology,
Inselspital, CH-3010 Bern, Switzerland (e-mail:
markus.borner@insel.ch).
1654 CORRESPONDENCE Journal of the National Cancer Institute, Vol. 94, No. 21, November 6, 2002
